🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

186 results for “Air” Clear

  1. KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Disc Medicine

    Mismatch repair deficient endometrial cancer / uterine cancer

    phase 2 small molecule active

    1 trial

  2. Lamivudina Aurovitas 300 mg comprimidos recubiertos con película EFG

    Meda AB

    Mild Cognitive impairment due to Alzheimer Disease

    phase 2 small molecule active

    1 trial

  3. Lynparza 100 mg film-coated tablets, IMFINZI 50 mg/mL concentrate for solution for infusion., Faslodex 250 mg solution for injection., Lynparza 150 mg film-coated tablets, Zoladex 3.6 mg Implant

    Cancer Prevention Pharma (Ireland) Limited

    ER-positive and HER2-negative metastatic or locally advanced breast cancer with either a germline or somatic BRCA mutation, or a deleterious alteration of other genes involved in homologous recombination repair (HRR) or in MSI status.

    phase 2 small molecule active

    1 trial

  4. Pluvicto 1 000 MBq/mL solution for injection/infusion, Locametz 25 micrograms kit for radiopharmaceutical preparation

    Novartis Ophthalmics Europe

    Progressive PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC) with moderate and severe renal impairment and with normal renal function.

    phase 2 small molecule active

    1 trial

  5. RElapse in previously irradiated Prostate bed : a phase I/II study of stereotactic Ablative reIRradiation potentiated by Metformine (REPAIR GETUG P16)

    CERO THERAPEUTICS HOLDINGS, INC.

    RElapse in previously irradiated Prostate bed

    phase 2 other active

    1 trial

  6. Rapamune 1 mg/mL oral solution

    Tour Hekla

    Lingual microcystic lymphatic malformations (LMLMs) are rare congenital vascular malformations, presenting as clusters of cysts filled with lymph fluid or blood. They are responsible for a heavy burden even with small well-limited lesions because of oozing, bleeding, infections, or even speech, chewing or breathing impairment. Pain and aesthetic prejudice are also frequently reported

    phase 2 small molecule active

    1 trial

  7. SAGE-718

    SUPERNUS PHARMACEUTICALS, INC.

    Mild Cognitive Impairment

    phase 2 small molecule completed

    1 trial

  8. Senicapoc

    BRIGHT MINDS BIOSCIENCES INC.

    Mild Cognitive Impairment

    phase 2 small molecule active

    1 trial

  9. Sodio ioduro (I131) Curium Netherlands 37-7400 MBq capsula rigida, -

    Fondazione Telethon ETS

    Metastatic DTC

    phase 2 small molecule active

    1 trial

  10. Tiragolumab, Tecentriq 1 200 mg concentrate for solution for infusion

    Disc Medicine

    HNSCC, metastatic deficient mismatch repair (dMMR)/MSI-high (MSI-H) tumors, irresectable or metastatic melanoma, locally advanced or metastatic solid tumor

    phase 2 small molecule active

    1 trial

  11. Valbenazine Oral Capsule

    NEUROCRINE BIOSCIENCES INC

    Trichotillomania (Hair-Pulling Disorder)

    phase 2 small molecule active

    1 trial

  12. Vonafexor, ROSUVASTATIN , IOHEXOL , Vonafexor

    Pharma Mar S.A.

    Impaired renal function and suspected MASH

    phase 2 small molecule active

    1 trial

  13. donepezil

    China SXT Pharmaceuticals

    Cognitive Impairment

    phase 2 small molecule active

    1 trial

  14. florquinitau F-18, VIZAMYL 400 MBq/mL solution for injection, [18F]PI-2620

    Institut für biomedizinische Analytik NMR-Imaging GmbH

    cognitive impairment

    phase 2 small molecule active

    1 trial

  15. 100 mg Resmetirom Tablet

    Madrigal Pharmaceuticals EU Limited

    Renal Impairment

    phase 1 small molecule completed

    1 trial

  16. 145 mg/m2 NKTR 102

    Nektar Therapeutics UK Limited

    Advanced or Metastatic Solid Tumors in Patients With Hepatic Impairment

    phase 1 small molecule completed

    1 trial

  17. 15O-WATER, Natriumklorid Fresenius Kabi, 9 mg/ml, infusionsvätska, lösning, AZD3427, Dopamin Fresenius 50 mg/5 ml, Konzentrat zur Herstellung einer Infusionslösung, Placebo for AZD3427 or AZD3427 diluent

    AstraZeneca AB

    Heart failure with reduced ejection fraction, Renal impairment

    phase 1 small molecule active

    1 trial

  18. A Phase I Study of Belantamab Mafodotin in Multiple Myeloma Participants with Normal and Impaired Hepatic Function

    GlaxoSmithKline Biologicals S.A.

    Relapsed or Refractory Multiple Myeloma

    phase 1 other active

    1 trial

  19. A Phase I Study of Belantamab Mafodotin in Multiple Myeloma Participants with Normal and Impaired Renal Function

    GlaxoSmithKline Biologicals S.A.

    Relapsed/Refractory Multiple Myeloma

    phase 1 other active

    1 trial

  20. A Phase I study to evaluate the safety and efficacy of L19IL2 in combination with ruxolitinib in patients with advanced solid tumors.

    Philogen S.p.A.

    Advanced solid tumors, specifically: • metastatic clear cell renal carcinoma • proficient mismatch repair / microsatellite stable (pMMR/MSS), BRAF-V600E-mutant negative colorectal carcinoma • locally advanced or metastatic pancreatic adenocarcinoma

    phase 1 other active

    1 trial

  21. A RANDOMIZED PHASE I, DOUBLE-BLIND, PARALLEL, COMPARATIVE ASSESSMENT OF PHARMACOKINETICS, SAFETY, PHARMACODYNAMICS, AND IMMUNOGENICITY OF LT-01 (AN OMALIZUMAB BIOSIMILAR CANDIDATE [TEST]) LYOPHYLIZED POWDER FOR SUBCUTANEOUS INJECTION VERSUS EU-APPROVED XOLAIR® LYOPHYLIZED POWDER FOR SUBCUTANEOUS INJECTION (REFERENCE) IN HEALTHY SUBJETCS: CIMA STUDY.

    Laboratorios Tillomed Spain S.L.U

    Chronic spontaneous urticaria, Allergic asthma, Chronic rhinosinusitis with nasal polyps

    phase 1 other active

    1 trial

  22. A Single Dose, Non-randomised, Open-label, Parallel Group Study to Assess the Pharmacokinetics, Safety, and Tolerability of AZD4144 in Participants with Severe Renal Impairment, End-stage Kidney Disease, and in Healthy Participants

    AstraZeneca AB

    Healthy Volunteers, Renal Impairment and End Stage Kidney Disease

    phase 1 other active

    1 trial

  23. A Single-Dose Pharmacokinetic Study of Eloralintide in Participants with Varying Degrees of Liver Impairment and Participants with Normal Liver Function

    Eli Lilly Co.

    Participants with Mild, Moderate, or Severe Hepatic Impairment and Participants with Normal Hepatic Function

    phase 1 other active

    1 trial

  24. A Single-Dose Pharmacokinetic Study of Lepodisiran in Participants with Varying Degrees of Liver Impairment and Participants with Normal Liver Function

    Eli Lilly Co.

    Normal Hepatic Function and Mild, Moderate, or Severe Hepatic Impairment

    phase 1 other active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources